Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)

• Published in: Annals of the rheumatic diseases Vol. 76; no. 1; pp. 203 - 207
• Main Authors: Strand, Vibeke, Mease, Philip, Gossec, Laure, Elkayam, Ori, van den Bosch, Filip, Zuazo, James, Pricop, Luminita, Mpofu, Shephard
• Format: Journal Article
• Language: English
• Published: England Elsevier Limited 01.01.2017; BMJ Publishing Group
• Subjects: Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic - drug therapy; Clinical outcomes; Drug Administration Schedule; Female; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - therapeutic use; Injections, Intravenous; Injections, Subcutaneous; Life Sciences; Male; Middle Aged; Patient Reported Outcome Measures; Psoriatic arthritis; Quality of Life; Severity of Illness Index; Treatment Outcome; Patient perspective; Treatment; Quality Indicators; Psoriatic Arthritis

ObjectiveTo evaluate the effect of secukinumab on patient-reported outcomes (PROs) in subjects with active psoriatic arthritis (PsA) in the FUTURE 1 study.MethodsSubjects were randomised 1:1:1 to receive intravenous (i.v.) secukinumab 10 mg/kg at weeks 0, 2 and 4 followed by subcutaneous secukinumab...